Apollomics, Inc. (NASDAQ:APLM) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ET Company Participants Guo Liang Yu - Chairman and Chief Executive Officer Sanjeev Redkar - Co-founder, Executive Director and President Matthew Plunkett - Chief Financial Officer Conference Call Participants Tim Moore - EF Hutton Operator Good morning ladies and gentlemen. Welcome to the Apollomics Full Year 2023 Results Conference Call. Before we begin, we want to advise you that over the course of the call and questio ...

Exhibit 99.1 Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results • Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program • Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025 • $37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025 • Management to host conferenc ...

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics. "It's our pleasure to welcome Matt to the Apollomics team. We expect his financial strategy and business development expertise from working with development and commercial stage public companies to ...

FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on January 16, 2024, it received a notification (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the ...

FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET. To access the l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...